CUPERTINO, Calif., Aug. 31,
2023 /PRNewswire/ -- DURECT Corporation
(Nasdaq: DRRX), a biopharmaceutical company committed
to transforming the treatment of acute organ injury and chronic
liver diseases by advancing novel and potentially lifesaving
therapies based on its endogenous epigenetic regulator
program, will present in the following September 2023 conferences.
|
H.C. Wainwright
25th Annual Global Investment Conference, September
11-13, 2023
|
|
Location:
|
New York City,
NY
|
|
Webcast
Presentation:
|
September 11, 2023, at
10:30 am ET
|
|
Link:
|
click HERE
|
|
|
|
Cantor Fitzgerald
Annual Global Healthcare Conference, September 26-28,
2023
|
|
Location:
|
New York City,
NY
|
|
Panel
presentation:
|
September 27, 2023 at
4:45 pm ET
|
|
Link:
|
click HERE
|
Presentation links will also be available by
accessing DURECT's homepage
at www.durect.com and clicking
on "Events" page under the "Investors" section. Management will be
available for one-on-one meetings during these conferences. Please
contact conference representatives or DURECT
directly.
About DURECT Corporation
DURECT is
a biopharmaceutical company committed to transforming the treatment
of acute organ injury and chronic liver diseases by advancing novel
and potentially lifesaving therapies based on its endogenous
epigenetic regulator program. Larsucosterol, DURECT's lead drug
candidate, binds to and inhibits the activity of DNA
methyltransferases (DNMTs), epigenetic enzymes which are elevated
and associated with hypermethylation found in alcohol-associated
hepatitis (AH) patients. Larsucosterol is in clinical development
for the potential treatment of AH, for which FDA has granted a Fast
Track Designation; non-alcoholic steatohepatitis (NASH) is also
being explored. In addition, POSIMIR® (bupivacaine
solution) for infiltration use, a non-opioid analgesic utilizing
the innovative SABER® platform technology, is
FDA-approved and has been exclusively licensed to Innocoll
Pharmaceuticals for commercialization in the United States. For more information about
DURECT, please visit www.durect.com and
follow us on Twitter
https://twitter.com/DURECTCorp.
DURECT Forward-Looking
Statements
This press release contains
forward-looking statements, including statements made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, relating to: our plans to report topline
data in the fourth quarter of 2023, the potential FDA
approval of larsucosterol for the treatment of AH, the
ability of a positive outcome in the AHFIRM trial to
support a New Drug Application filing, our plans to
commercialize larsucosterol if approved, the
commercialization of POSIMIR by Innocoll,
the potential to develop larsucosterol for AH, NASH or
other indications, and the potential benefits, if any, of our
product candidates. Actual results may differ materially from those
contained in the forward-looking statements contained in this press
release, and reported results should not be considered as an
indication of future performance. The potential risks and
uncertainties that could cause actual results to differ from those
projected include, among other things, the risks that the
AHFIRM trial takes longer to complete than anticipated, the
risk that ongoing and future clinical trials of
larsucosterol do not confirm the results from earlier
clinical or pre-clinical trials, or do not demonstrate the safety
or efficacy of larsucosterol in a statistically
significant manner, the risk that the FDA or other government
agencies may require additional clinical trials for
larsucosterol before approving it for the treatment of AH
even if the results of the AHFIRM trial are
successful, risks that Innocoll may not
commercialize POSIMIR successfully, and risks related
to the sufficiency of our cash resources, our anticipated capital
requirements and capital expenditures, our need or desire for
additional financing, our ability to obtain capital to fund our
operations and expenses and our ability to continue to operate as a
going concern. Further information regarding these and other risks
is included in DURECT's most recent Securities and
Exchange Commission (SEC) filings, including its annual report on
Form 10-K for the year ended December 31,
2022 and quarterly report on Form 10-Q for the quarter ended
June 30, 2023 when filed under the
heading "Risk Factors." These reports are available on our
website www.durect.com under
the "Investors" tab and on the SEC's website at
www.sec.gov. All information provided in this
press release and in the attachments is based on information
available to DURECT as of the date hereof,
and DURECT assumes no obligation to update this
information as a result of future events or developments, except as
required by law.
NOTE: POSIMIR® is a trademark of Innocoll
Pharmaceuticals, Ltd. in the U.S. and a trademark of DURECT
Corporation outside of the U.S. SABER® is a trademark of
DURECT Corporation. Other referenced trademarks belong to their
respective owners. Larsucosterol (DUR-928) is an investigational
drug candidate under development and has not been approved for
commercialization by the U.S. Food and Drug Administration or other
health authorities for any indication.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/durect-corporation-announces-presentations-in-upcoming-investor-conferences-301915291.html
SOURCE DURECT Corporation
